Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

12.56
HKD
-0.04
(-0.32%)
1.33EPS
10.27P/E
39.11BMarket Cap
Mar 12Next Earn

Total Valuation

HKD

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H carries a market capitalization of 39.11B, placing it among publicly traded companies globally. Its enterprise value stands at 50.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap39.11B
Enterprise Value50.24B

Important Dates

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H's next confirmed earnings release is scheduled for March 12, 2027.

Earnings Date3/12/2027

Share Statistics

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 2.94B shares outstanding.

Shares Outstanding2.94B

Valuation Ratios

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H trades at a trailing price-to-earnings ratio of 10.27. The price-to-sales ratio is 0.28, and the price-to-book ratio stands at 0.86.

PE Ratio10.27
PS Ratio0.28
PB Ratio0.86
P/TBV Ratio0.96

Enterprise Valuation

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H trades at an EV/EBITDA multiple of 16.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 50.24B versus a market cap of 39.11B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.55
EV / EBITDA16.02
EV / EBIT16.02

Financial Position

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H maintains a current ratio of 1.64, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.02, indicating elevated leverage, while an interest coverage ratio of 6.47 demonstrates adequate ability to service its debt obligations.

Current Ratio1.64
Quick Ratio0.32
Debt / Equity46.02
Debt / EBITDA7.11
Interest Coverage6.47

Financial Efficiency

HKD

Over the twelve months ended September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H posted a return on equity (ROE) of 5.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.21, useful for judging operating efficiency across full business cycles. The company generates approximately 3.38M in revenue per employee across its workforce of 27,057.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.63 indicates how many times Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)5.64
Return on Assets (ROA)2.55
Return on Invested Capital (ROIC)3.79
Return on Capital Employed (ROCE)4.21
Revenue Per Employee3.38M
Employee Count27,057.00
Inventory Turnover5.63

Taxes

HKD

Over the twelve months ended September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H recorded 539.64M in income tax expense. That works out to an effective tax rate of 17.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.15B, leaving 2.53B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax539.64M
Effective Tax Rate17.15

Stock Price Statistics

HKD

As of the close on November 17, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H's stock has declined approximately 36.69% over the past 52 weeks. The 50-day moving average sits at 13.10, while the 200-day moving average is 15.68.

52-Week Price Change-36.69%
50-Day Moving Average13.10
200-Day Moving Average15.68

Income Statement

HKD

Over the twelve months ended September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H generated 91.43B in revenue and converted that into 2.53B in net income, yielding earnings per share of 1.33. EBITDA reached 3.14B, while operating income came in at 3.15B.

Revenue91.43B
Gross Profit13.92B
Operating Income3.15B
Pretax Income3.15B
Net Income2.53B
EBITDA3.14B
EBIT3.14B
Earnings Per Share (EPS)1.33

Balance Sheet

HKD

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H holds 13.93B in cash and equivalents against 22.29B in total debt, resulting in a net debt position of 6.60B. Total book value stands at 45.68B, with working capital of 28.34B providing operational flexibility.

Cash & Cash Equivalents13.93B
Total Debt22.29B
Net Debt6.60B
Equity (Book Value)45.68B
Book Value Per Share15.55
Working Capital28.34B

Cash Flow

HKD

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-1.27B

Margins

Over the twelve months ended September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H posted a gross margin of 15.22, reflecting its pricing power and cost economics. The operating margin of 3.45 and net profit margin of 2.77 provide insight into operational efficiency.

Gross Margin15.22
Operating Margin3.45
Pretax Margin3.44
Profit Margin2.77
EBITDA Margin3.43

Dividends & Yields

HKD

Over the twelve months ended September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H paid dividends of 0.95 per share. The dividend payout ratio of 69.23 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -4.19, meaning Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.95
Payout Ratio69.23
Shareholder Yield-4.19

Scores

As of September 30, 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has an Altman Z-Score of 2.25, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.25